Anaesthesiological experience with whole body hyperthermia

International Journal of Hyperthermia

Volumn 19, Issue 1, 2003, Pages 1-12

  Kerner, Thoralf ^a   Hildebrandt, B ^a   Ahlers, O ^a   Deja, M ^a   Riess, H ^a   Draeger, J ^a   Wust, P ^a   Gerlach, H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Haemodynamic monitoring; Systemic Cancer Multistep Therapy; Whole body hyperthermia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANESTHETIC AGENT; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; CREATININE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; FUROSEMIDE; GAMMA GLUTAMYLTRANSFERASE; IFOSFAMIDE; MITOMYCIN C; PROPOFOL; REMIFENTANIL; UREA; VECURONIUM;

ADULT; AGED; ANESTHESIOLOGICAL TECHNIQUES; ANESTHESIOLOGY; ARTERY CATHETER; ARTICLE; BLOOD PRESSURE; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR PARAMETERS; CENTRAL NERVOUS SYSTEM FUNCTION; CIRCULATION; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL OBSERVATION; CLINICAL TRIAL; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOSTASIS; DEVICE; DISSEMINATED CANCER; EVALUATION; EXPERIENCE; FEMALE; FEMORAL ARTERY; GENERAL ANESTHESIA; GERM CELL TUMOR; HEART STRESS; HEMODYNAMIC MONITORING; HUMAN; HYPERTHERMIC THERAPY; KIDNEY FUNCTION; LIVER FUNCTION; LUNG; LUNG EDEMA; LUNG EXTRAVASCULAR FLUID; LUNG FUNCTION; LYMPHOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; OVARY CANCER; OXIMETRY; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RADIAL ARTERY; SAFETY; SUPRAVENTRICULAR TACHYCARDIA; SYMPTOM; UTERINE CERVIX CANCER; COLORECTAL TUMOR; HEMODYNAMICS; KIDNEY; METHODOLOGY; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PHYSIOLOGY; UTERINE CERVIX TUMOR;

ADULT; ANESTHESIOLOGY; COLORECTAL NEOPLASMS; FEMALE; FEMORAL ARTERY; GERMINOMA; HEMODYNAMIC PROCESSES; HUMANS; HYPERTHERMIA, INDUCED; KIDNEY; LUNG; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; RADIAL ARTERY; UTERINE CERVICAL NEOPLASMS;

EID: 0037228733     PISSN: 02656736     EISSN: None     Source Type: Journal    
DOI: 10.1080/02656730210143596     Document Type: Article

References (42)

1. Valdagni R, Amichetti M. Report of a long-term follow-up in a randomized trial comparing radiation therapy and radiation plus hyperthermia to metastatic lymph nodes in stage IV head and neck cancer patients. Int J Radiat Oncol 1993; 28: 163-9.
2. Van Der Zee J, Gonzalez Gonzalez D, Van Rhoon GC, Can Dijk JDP, Van Putten WLJ, Hart AAM. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumors: A prospective, randomised, multicentre trial. Lancet 2000: 355: 1119-25.
3. Vernon CC, Hand JW, Field SB, Machin D, Whaley JB, Van Der Zee J, Van Putten WL, Van Rhoon GC, Van Dijk JD, Gonzalez Gonzalez D, Liu FF, Goodman P, Sherar M. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials. Int J Radiat Oncol Biol Phys 1996; 35: 731-44.
4. Overgaard J, Gonzalez-Gonzalez D, Hulshoff MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 1995; 345: 540-3.
5. Robins HI, Dennis WH, Neville AJ, Shecterle LM, Martin PA, Grossman J, Davis TE, Neville SR, Gillis WK, Rusy BF. A nontoxic system for 41.8°C whole-body hyperthermia: Results of a Phase I study using a radiant heat device. Cancer Res 1985; 45: 3937-44.
6. Wust P, Riess H, Hildebrandt B, Loffel J, Deja M, Ahlers O, Kerner T, Von Ardenne A, Felix R. Feasibility and analysis of thermal parameters for the whole-body-hyperthermia system IRATHERM-2000. Int J Hyperthermia 2000; 16: 325-39.
7. Wehner H, Von Ardenne A, Kaltofen S. Whole-body hyperthermia with waterfiltered infrared radiation: Technical aspects and clincial experiences. Int J Hyperthermia 2001; 19: 19-30.
8. Robins HLI, Cohen JD, Schmitt CL, Tutschk KD, Feierabend C, Arzoomanian RZ, Alberti D, D'Oleire F, Longo W, Heiss C, Rushing D, Love R, Spriggs D. Phase I clinical trial of carboplatin and 41.8°C whole-body hyperthermia in cancer patients. J Clin Oncol 1993; 9: 1787-94.
9. Robins HI, Rushing D, Kutz M, Tutsch KD, Tiggelaar CL, Paul D, Spriggs D, Kraemer C, Gillis WK, Feierabend C, Arzoomanian RZ, Longo W, Alberti D, D'Oleire F, Qu RP, Wilding G, Stewart JA. Phase I clinical trial of melphalan and 41.8°C whole-body hyperthermia in cancer patients. J Clin Oncol 1997; 15: 158-64.
10. Wiedemann GJ, Katschinsky DM, Mentzel M, D'Oliere F, Wagner T, Robins HI. Ifosfamide, carboplatin and etoposide combined with aquatherm induced 41.8°C wholebody hyperthermia (WBH) for refractory sarcoma. J Clin Oncol 1996; 14: 1751.
11. Hegewisch-Becker S, Gruber Y, Panse J, Atanackowic D, Niehaus A, Hossfeld DK. Whole-body hyperthermia (WBH 41.8°C) as an adjunct to oxliplatin (OXA)/5-FU/FA in high-dose (HD)-5-FU/FA or HD-5-FU/FA and CPT-11 refractory/relapsed advanced colorectal cancer. Ann Oncol 2000; 11: 67.
12. Rjosk D, Bergauer F, Janni W, Strobl B, Pohl K, Buchfelder A, Sommer H. Phase II trial evaluating safety and efficacy of chemotherapy with carboplatin and paclitaxel combined with extreme whole body hyperthermia in patients with ovarian cancer. Ann Oncol 2000; 11(Suppl 4): 86
13. Bakshandeh A, Bruns I, Eberhardt K, Demedts A, Kaukel E, Gatzemeier U, Dhalhoff K, Jäger E, Jäger D, Knuth A, Hegewisch-Becker S, Hossfeld DK, Wiedemann GJ. Ifosfamide, carboplatin and etoposide combined with aquatherm-induced 41.8°C whole-body hyperthermia for adult patients with malignant pleural mesothelioma. Ann Oncol 2000; 11(Suppl. 4): 113.
14. Kerner T, Deja M, Ahlers O, Loffell J, Hildebrandt B, Wust P, Gerlach H, Reiss H. Whole body hyperthermia: A secure procedure for patients with various malignancies? Intensive Care Med 1999; 25: 959-65.
15. Stern DH, Gerson JI, Allen FB, Parker FB. Can we trust the direct radial artery pressure immediately following cardiopulmonary bypass? Anesthesiology 1985; 62: 557-61.
16. Pauca AL, Hudspeth AS, Wallenhaupt SL, Tucker WY, Kon ND, Mills SA, Cordell AR. Radial artery-to-aorta pressure difference after discontinuation of cardiopulmonary bypass. Anesthesiology 1989; 70: 935-41.
17. Gravlee GP, Brauer SD, O'Rourke MF, Avolio AP. A comparison of brachial, femoral, and aortic intra-arterial pressures before and after cardiopulmonary bypass. Anaesth Intensive Care 1989; 17: 305-11.
18. Rich GF, Lubanski REJ, McLoughlin TM. Differences between aortic and radial artery pressure associated with cardiopulmonary bypass. Anesthesiology 1992; 77: 63-6.
19. Hynson JM, Sessler DI, Moayeri A, Katz JA. Thermoregulatory and anesthetic-induced alterations in the differences among femoral, radial, and oscillometric blood pressures. Anesthesiology 1994; 81: 1411-21.
20. Barlogie B, Corry PM, Yip E, Lippmann L, Johnston DA, Khalil K, Teuzynski TF, Reilly E, Dosik G, Rigor B, Hankenson EJ, Freireich EJ. Total-body hyperthermia with and without chemotherapy for advanced human neplasma. Cancer Res 1979; 39: 1481-9.
21. Herman TS, Sweets CC, White DM, Gerner EW. Effect of heating on lethality due to hyperthermia and selected chemotherapeutic drugs. J Natl Cancer Inst 1982; 68: 487-91.
22. Larkin JM. A clinical investigation of total body hypethermia as cancer therapy. Cancer Res 1979; 39: 2252-4.
23. Van Der Zee J, Van Rhoon G, Wike-Hooley JJ, Faithfull S, Reinhold HS. Whole-body hyperthermia in cancer therapy. A report of a phase I/II study. Eur J Cancer Clin Oncol 1983; 19: 1189-200.
24. Robins HI, Longo WL, Lagoni RK, Neville AJ, Riggs C, Schmitt CL, Hugander A, Young C. A phase I trial of lonidamine with whole body hyperthermia in advanced cancer. Cancer Res 1988; 43: 6587-92.
25. Steinhausen D, Mayer WK, Ardenne M. Evaluation of systemic tolerance of 42.0°C Infrared-A whole-body hyperthermia in combination with hyperglycemia and hyperoxemia. A phase-I study. Strahlenther Onkol 1994; 170: 322-34.
26. Parks LC, Minaberry D, Smith DP, Neely WA. Treatent of far-advanced bronchogenic carcinoma by extracorporeally induced systemic hyperthermia. J Thorac Cardiovasc Surg 1979; 78: 883-92.
27. Pettigrew RT, Galt JM, Ludgate CM, Horn DB, Smith AN. Circulatory and biochemical effects of whole body hyperthermia. Br J Surg 1974; 61: 727-30.
28. Kim YD, Lake CR, Lees DE, Schuette WH, Bull JM, Weise V, Kopin IJ. Hemodynamic and plasma catecholamine responses to hyperthermic cancer therapy in humans. Am J Physiol 1979; 237: H570-4.
29. Lees DE, Kim YD, Bull JM, Whang Peng J, Schuette W, Smith R, Macnamara TE. Anesthetic management of whole-body hyperthermia for the treatment of cancer. Anesthesiology 1980; 52: 418-28.
30. Ostrow S, Van Echo D, Whitacre M, Aisner J, Simon R, Wiernik PH. Physiologic response and toxicity in patients undergoing whole-body hyperthermia for the treatment of cancer. Cancer Threat Rep 1981; 65: 323-5.
31. Faithfull NS, Reinhold HS, Van Den Berg AP, Van Rhoon GC, Van Der Zee J, Wike-Hooley JL. Cardiovascular changes during whole body hyperthermia treatment of advanced malignancy. Eur J Appl Physiol 1984; 53: 274-81.
32. Robins H, Hugander A, Besozzi M, Schmitt CL, Martin PA, Zager LV, Grossman J. Beta-blockade during whole-body hyperthermia: A toxicity study in the dog. Int J Hyperthermia 1991; 7: 263-70.
33. Berry JM, Michalsen A, Nagle V, Bull JM. The use of esmolol in whole-bdy hyperthermia: Cardiovascular effects. Int J Hyperthermia 1997; 13: 261-8.
34. Urzua J. Aortic-to-radial arterial pressure gradient after bypass. Anesthesiology 1990; 73: 191.
35. Brengelmann GL. Circulatory adjustments to exercise and heat stress. Ann Rev Physiol 1983; 45: 191-212.
36. Hynson JM, Katz JA, Mangano DT. On the accuracy of intra-arterial pressure measurement: The pressure gradient effect. Crit Care Med 1998; 26: 1623-4.
37. Sessler DI, Moayeri A, Stone R, Glosten B, Hynson J, McGuire J. Thermoregulatory vasoconstriction decreases cutaneous heat loss. Anesthesiology 1990; 73: 656-60.
38. Foxall PJ, Singer JM, Hartley JM, Neild GH, Lapsley M, Nicholson JK, Souhami RL. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy. Clin Cancer Res 1997; 3: 1507-18.
39. Brauer LP, Prieshof B, Wiedemann GJ, Weiss C, Kriz W, Schramm U, Robins HI, Pagel H. Whole-body hyperthermia combined with ifosfamide and carboplatin causes hypotension and nephrotoxicity. J Cancer Res Clin Oncol 1998; 124: 549-54.
40. Gruber Y, Hegewisch-Becker S, Bakshandeh-Bath A, Sommer H, Hoffmann R, Hossfeld DK. Whole-body hyperthermia at 41.8°C combined with ifosfamide and carboplatin in relapsed ovarian carcinoma pretreated with a platin-containing regimen. Ann Oncol 2000; 11(Suppl 4): 86.
41. Page RL, Meyer RE, Thrall DE, Dewhirst MW. Cardiovascular and metabolic response of tumour-bearing dogs to whole body hyperthermia. Int J Hyperthermia 1987; 3: 513-25.
42. Pereira Arias AM, Wester JPJ, Blankendaal M, Schilthuis MS, Kuijper EJ, Rademaker BMP, Stoutenbeek CP, Rierbroek RC. Multiple organ dysfunction syndrome induced by whole-body hyperthermia and polychemotherapy in a patient with disseminated leiomyosarcoma of the uterus. Intensive Care Med 1999; 25: 1013-6.